Contrasting Compass Therapeutics (NASDAQ:CMPX) and Akebia Therapeutics (NASDAQ:AKBA)

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Compass Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Profitability

This table compares Compass Therapeutics and Akebia Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Compass Therapeutics N/A -49.93% -43.76%
Akebia Therapeutics -22.60% -156.59% -11.53%

Valuation & Earnings

This table compares Compass Therapeutics and Akebia Therapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Compass Therapeutics $850,000.00 163.95 -$66.49 million ($0.47) -1.65
Akebia Therapeutics $236.20 million 0.56 -$5.34 million ($0.16) -2.96

Akebia Therapeutics has higher revenue and earnings than Compass Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Compass Therapeutics and Akebia Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics 1 3 12 1 2.76
Akebia Therapeutics 1 2 4 0 2.43

Compass Therapeutics currently has a consensus price target of $9.99, indicating a potential upside of 1,191.25%. Akebia Therapeutics has a consensus price target of $3.90, indicating a potential upside of 722.44%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Akebia Therapeutics.

Summary

Compass Therapeutics beats Akebia Therapeutics on 11 of the 15 factors compared between the two stocks.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors.

About Akebia Therapeutics

(Get Free Report)

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.